Kornimate/medical-research-clean huggingface dataset:
the effect of multiple medications on the incidence of organic dyspepsia

Conditions: Dyspepsia

Summary: dyspepsia is a very common gastrointestinal disease, presented as predominant symptom of upper abdominal pain. underlying causes for dyspepsia can classified as organic or functional dyspepsia. some medications (eg. non-steroid anti-inflammatory drugs (nsaids)) were associated with higher frequent incidences of organic lesions. multiple medications showed an increased trend with aging of the population and multimorbidity. multiple medications were suggested to be strongly relate to adverse drug events (ades), adverse drug reactions (adrs), drug-drug interactions, and drug-disease interactions, which had been reported to lead to higher incidences of some diseases, including fractures, cognitive impairment and malnutrition. however, it was unknown if multiple medications was associated with more incidences of organic dyspepsia.


Eligibility criteria:
inclusion criteria: 1. aged ≥18 years old 2. patients who met broad criteria of dyspepsia 3. undergoing upper endoscopy and abdominal ultrasonography within one year. exclusion criteria: 1. organ failure defined by marshall standard 2. severe psychiatric illnesses 3. suspected or identified bowel obstruction 4. known malignancy 5. pregnancy or lactation 6. unable to provide consent
effects of a single session of physiotherapy on patients operated for lumbar spondylolisthesis

Conditions: Spondylolisthesis

Summary: the goal of this clinical trial is to investigate whether a meeting with physiotherapist before hospital discharge can improve the post-operative outcomes in patients who have undergone lumbar fusion surgery for spondylolisthesis. the main question it aims to answer is: * the primary endpoint investigated is the degree of disability measured using the odi-i one month after the surgical intervention. * the secondary endpoints are the level of pain measured using the nrs scale at 1 and 3 months post-surgery; disability at 3 months measured using the odi-i questionnaire; physical function assessed using the uwt at 1 and 3 months post-surgery; psychological factors such as self-efficacy and fear of movement measured using the tsk and pseq-i at 1 and 3 months after lumbar fusion surgery; health status and quality of life measured at 3 months with the hads-i and sf-36-i questionnaires; and the patient's satisfaction regarding their hospital stay, assessed using a prems questionnaire administered at the time of discharge. the "usual care" group will instead be discharged by the spinal surgeon following the standard procedures. the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercise to be performed at home until the next visit, one month after surgery. additionally, the patient will have the opportunity to communicate, either by email or phone, with the physiotherapist until the follow-up visit with the spinal surgeon.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patients who have undergone lumbar fusion surgery due to monosegmental lumbar spondylolisthesis. exclusion criteria: * patients who have undergone previous lumbar surgeries * patients operated on for other lumbar pathologies * patients with pre-existing neurological deficits not related to the condition being treated * patients with systemic conditions (inflammatory, infectious, neoplastic, etc.) or neuromuscular disorders * patients with cognitive deficits or psychiatric disorders * patients who do not speak italian fluently

Keywords: lumbar spondylolisthesis physiotherapy disability psychological factors randomized controlled trial
hemodynamic and respiratory variations during laparoscopic surgery with and without deep neuromuscular blockade.

Conditions: Intraoperative Complications; Postoperative Complications; Laparoscopy; Surgical Complications From General Anesthesia; Ventilator-Induced Lung Injury

Summary: the goal of this study is to investigate the effect of depth of neuromuscular block (nmb) on global and regional (dependent versus nondependent) respiratory mechanics during laparoscopic surgery. furthermore, we will investigate if the level of nmb influences intraoperative hemodynamic and cerebral oxygenation.


Eligibility criteria:
inclusion criteria: * age 18 years or older * elective patients scheduled to undergo laparoscopic surgery with expected duration \> 2h * physical status asa i - iii exclusion criteria: * pregnancy * severe cardiac disease (nyha class iii or iv, acute coronary syndrome, or persistent ventricular tachyarrhythmia) * previous lung surgery * history of severe chronic obstructive pulmonary disease * gastro-esophageal pathology (including but not limited to recent gastric or esophageal surgery including bypass/banding, history of esophageal varices, known anatomical gastric or esophageal defects such as strictures, hernias or fistulas) * mechanical ventilation within the last 30 days * neuromuscular disease * consented for another interventional study or refusal to participate in the present study * hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents

Keywords: tomography oximetry echocardiography
belzutifan/mk-6482 for the treatment of advanced pheochromocytoma/paraganglioma (ppgl), pancreatic neuroendocrine tumor (pnet), von hippel-lindau (vhl) disease-associated tumors, advanced gastrointestinal stromal tumor (wt gist), or solid tumors with hif-2α related genetic alterations (mk-6482-015)

Conditions: Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers

Summary: this is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (ppgl), pancreatic neuroendocrine tumor (pnet), von hippel-lindau (vhl) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt gist), or advanced solid tumors with hypoxia inducible factor-2 alpha (hif-2α) related genetic alterations. the primary objective of the study is to evaluate the objective response rate (orr) of belzutifan per response evaluation criteria in solid tumors version 1.1 (recist 1.1) by blinded independent central review (bicr).


Eligibility criteria:
the main inclusion criteria include but are not limited to the following: * male and female participants at least 12 years of age (at least 18 years of age for cohort b1) * diagnosis of one of the following: advanced/metastatic pheochromocytoma/paraganglioma (ppgl), pancreatic neuroendocrine tumors (pnet), von hippel-lindau (vhl) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt gist) or advanced solid tumors with hypoxia inducible factor- 2 alpha subunit (hif-2α) related genetic alterations * cohort bi: vhl disease-associated tumors: * have a diagnosis of vhl disease as determined by a germline test locally and/or clinical diagnosis * must be ≥18 years of age * has a life expectancy of at least 3 months the main exclusion criteria include but are not limited to the following: * unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan * history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * any of the following: a pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen * clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (cabg) or percutaneous transluminal coronary angioplasty (ptca) ≤6 months from study entry, or new york heart association class iii or iv congestive heart failure * received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention

Keywords: hif-2α pheochromocytoma/paraganglioma pancreatic net
outreach visits to optimize chronic care management in general practice: a cluster randomized trial

Conditions: Chronic Disease

Summary: the aim of this project is to motivate and support general practice clinics in implementing the visions and recommendations presented in two of the disease specific programmes for chronic care management (for chronic obstructive lung disease and type 2 diabetes). these programmes describe evidence based treatment and division of tasks between the municipalities, the hospitals and general practice. the facilitator project is funded by the danish ministry of interior and health.

in a cluster randomized trial the investigators will explore the efficacy of up to three outreach visits by specially trained gps. efficacy data are obtained by means of questionnaires at regional databases.

Eligibility criteria:
inclusion criteria: general practices working in the capital region in denmark exclusion criteria: general practices where the facilitator works.

Keywords: health services research chronic care outreach visits primary care chronic disease management
laser vision correction use of an eye shield for maintaining vision and mitigating pain

Conditions: Post Laser Vision Correction Pain and Discomfort

Summary: the purpose of this research is to determine if an investigational thin shield can effectively reduce discomfort following laser vision correction.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo laser vision correction for correction of refractive error * fda approved treatment guidelines for laser vision correction * age 18-60 * patients able to understand the requirements of the study, willing to follow study instructions, provide written informed consent to participate, and comply with all study requirements, including the required study follow-up visits exclusion criteria: * any other anterior segment abnormality other than that associated with laser vision correction * any abnormalities associated with the eye lids * uncontrolled blepharitis or dry eye * prior laser treatment of the retina * any ophthalmic surgery performed within three (3) months prior to study excluding prk or lasik * diagnosis of glaucoma * active diabetic retinopathy * clinically significant inflammation or infection within six (6) months prior to study * uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of the investigator * participation in any study involving an investigational drug within the past 30 calendar days, or ongoing participation in a study with an investigational material * intolerance or hypersensitivity to topical anesthetics, antibiotics, steroids or any other pharmaceuticals that may be used pre and post surgically * specifically known intolerance or hypersensitivity to contact lenses or any component of the investigative material * a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up * any condition that, in the opinion of the investigator, would jeopardize the safety of the patient * pregnancy
phase 2 amg 714 in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: twelve week treatment of amg 714 in ra patients who failed at least one dmard, followed by a 3 month observational period.


Eligibility criteria:
inclusion criteria: diagnosis of ra - exclusion criteria: no prior biologic treatment for ra -
investigation of the effectiveness of structured education according to premenstrual syndrome symptom map

Conditions: Premenstrual Syndromes; Education; Menstrual Cycle Disorder

Summary: in this study, it was aimed to evaluate the effectiveness of the training structured according to the pms symptom map. this experimental (randomised-controlled) study was conducted with women of reproductive age with pms. women who met the inclusion criteria and volunteered to participate in the study constituted the sample of the study. as a result of block randomisation, 55 women were assigned to the intervention group and 55 women to the control group. pre-test data were collected from the women allocated to the intervention and control groups by means of data collection tools (vas pain scoring, das depression stress anxiety assessment scale, premenstrual syndrome assessment scale and premenstrual syndrome-specific life satisfaction scale). the intervention group received a 3-session structured training according to the pms symptom map, while the control group did not receive any intervention. women in the intervention group completed the post-test data on the last day of the 2nd cycle after the training, while women in the control group completed the post-test data on the last day of the 2nd cycle after the pre-test.


Eligibility criteria:
inclusion criteria: meeting acog's pms diagnostic criteria being over 18 years of age, not using psychotherapeutic medications, not having a mental illness, not being pregnant, agreeing to participate in the study exclusion criteria: not having regular menstruation in the last 3 months, using analgesics during menstruation while participating in the study.

Keywords: life satisfaction pain depression stress anxiety
efficacy and safety evaluation of the thromboaspiration catheter system instroke in patients with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: first prospective, single-arm, single-centre study to evaluate the efficacy and safety of the instroke thromboaspiration catheter system (instroke) for stroke in patients with acute ischemic stroke.

this is a prospective, single-arm, single-centre clinical safety and efficacy research. the purpose of the study is to evaluate safety and efficacy the device designed by ivascular for thromboaspiration (instroke) in patients who have suffered a stroke and who undergo thromboaspiration due to an acute occlusion of neuro vessels.

Eligibility criteria:
inclusion criteria: 1. patients with acute ischaemic stroke over 18 years of age caused by large vessel occlusion (tica, extracranial ica, m1, vertebral artery segment v4 or basilar artery) and receiving neurointerventional treatment with the instroke aspiration catheter. 2. informed consent signed by the patient or their representative, or deferred informed consent to avoid delaying commencement of mechanical thrombectomy. 3. patients with an aspects (alberta stroke program early ct score) score ≥ 6 4. in patients having onset of stroke more than 8 hours previously, wake-up strokes, or unknown time of onset, treatment must be customised and ct perfusion must show penumbra. 5. initial nihss score before procedure \> 6. exclusion criteria: 1. patients under 18 years of age. 2. patients with an aspects score \<6. 3. baseline nihss obtained before procedure of ≤ 6 points. 4. severe comorbidity and/or shortened life expectancy 5. mrs \> 2. 6. serious allergy to contrast medium. 7. pregnant women. 8. patients with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection 9. personal history of thrombocytopaenia (\<40,000 platelets)

Keywords: stroke ischemia thromboaspiration
impact of angiotensin converting enzyme activity on exercise training sensitivity

Conditions: Exercise; Angiotensin-Converting Enzyme Inhibitors

Summary: the phenotype based on the insertion/deletion (i/d) polymorphism of the human angiotensin converting enzyme (ace) gene has been associated with individual training response. briefly, intervention studies have demonstrated an 11-fold greater training-induced improvement in muscular endurance for ace i/i homozygotes compared to ace d/d homozygotes. importantly, the ace i/d polymorphism causes large inter-individual differences in serum ace activity. because the ace d/d genotype is characterized by high plasma ace activity and potentially blunted endurance exercise training response, it appears likely that ace inhibitors (acei) have the potential to improve the outcome of exercise training for ace d/d homozygotes. thus, in the present study the investigators apply a randomized double-blind placebo-controlled longitudinal design to investigate whether pharmacological inhibition of ace activity can amplify the exercise training response in healthy humans carrying either the ace d/d or ace i/i genotype. the study hypothesis is that inhibition of ace activity in healthy humans with the ace d/d genotype will amplify the health beneficial effects of exercise training while this is not the case in ace i/i homozygotes.


Eligibility criteria:
inclusion criteria: * aged 20-50 years * healthy exclusion criteria: -

Keywords: adaptation, physiological genotype polymorphism, genetic enalapril physiological effects of drugs
follow-up after metastasectomy in patients with kidney cancer

Conditions: Renal Cell Carcinoma

Summary: this phase ii trial studies the follow-up after metastasectomy in patients with kidney cancer. following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.

primary objectives: i. to assess the 24-week progression free/relapse free survival rate in patients undergoing metastasectomy for metastatic renal cell carcinoma (mrcc). secondary objectives: i. to evaluate progression free survival (pfs), relapse free survival (rfs) and overall survival (os) in patients undergoing metastasectomy. ii. to evaluate tissue determinants predictive for resectability, pfs and os in patients undergoing metastasectomy. outline: after metastasectomy, patients are followed up every 6 months for up to 5 years.

Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically confirmed renal cell carcinoma (rcc) * patients have clinical reasons for undergoing a surgical resection of tumor; there are two main categories of patients: * patients with fully resectable disease as defined by lesions accessible by a surgeon during no more than two separate surgical sessions, and are expected to be rendered surgically no evidence of disease (ned) * patients undergoing a noncurative procedure for relief of symptoms or for management of threatening lesions * patients have been deemed resectable by the subspecialty surgeon involved in the patient's care * patients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy; the only approved consent is attached to this protocol * patients must have ability to comply with study and/or follow-up procedures * members of all races and ethnic groups are eligible for this trial exclusion criteria: * patients must not have active acute infections that could be worsened by surgery or interfere with this study * patients must not have clinically significant cardiovascular disease, or peripheral vascular disease that creates an unacceptably high operative risk * patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates surgical resection, or render the subject at high risk from treatment complications * patients must not have a history of uncontrolled severe depression
psychosocial pain management to improve opioid use disorder treatment outcomes

Conditions: Opioid-use Disorder; Medication Assisted Treatment; Chronic Pain

Summary: the purpose of this research study is to look at the effect of programs aimed at helping people manage chronic pain and medication treatment. the program sessions focus on educational information and strategies for pain and medication management. the researchers enroll people who have chronic pain and have recently begun buprenorphine treatment to see if participants could benefit from these programs. this research study will help the researchers learn how to improve current therapies for pain and medication management.


Eligibility criteria:
inclusion criteria: * having a diagnosis of an opioid use disorders (oud) within the past 12 months; * started buprenorphine (the term we use to refer to all buprenorphine products including buprenorphine/naloxone) treatment within the past 6 months * at least moderate or greater self-reported pain on average over the past 3 months; * regular and consistent access to a telephone and willingness to use the phone for study sessions. exclusion criteria: * buprenorphine medication prescribed in the form of a monthly injection and/or a transdermal patch * self-reported pregnancy at the time of study enrollment * currently living outside of the united states

Keywords: psychosocial pain management buprenorphine
safety and efficacy of pilocarpine ophthalmic topical cream for the treatment of presbyopia

Conditions: Presbyopia

Summary: this is a multicenter, randomized, double-masked placebo-controlled, parallel group phase 2 trial evaluating the safety and efficacy of pilocarpine ophthalmic topical cream for the treatment of presbyopia.


Eligibility criteria:
inclusion criteria: * presbyopic male or female 40-55 years of age * willing and able to provide written informed consent on the irb/iec approved informed consent form exclusion criteria: * sensitivity or known allergy to pilocarpine or any of the other excipients of the formulation * history of eczema, dermatitis or skin sensitivity to over-the-counter personal care products * history of, or active, iritis or uveitis in either eye * pre-existing retinal diseases in either eye that may pre-dispose the subjects to retinal detachment

Keywords: pilocarpine refractive errors loss of near vision
feeding and swallowing problems in infants with laryngomalacia

Conditions: Feeding Disorders; Swallowing Disorder; Laryngomalacia

Summary: observational cross-sectional study infants with laryngomalacia feeding and swallowing assessment

identification of swallowing and feeding disorders in infants with laryngomalacia. identify if there is relation between severity of laryngomalacia and feeding and swallowing disorder.

Eligibility criteria:
inclusion criteria: * infants up to 2 years old diagnosed with laryngomalacia. * full term infants. exclusion criteria: * infants with other possible causes of dysphagia e.g., craniofacial anomalies, bdmh and neurological affection secondary to birth trauma, hypoxic ischemic encephalopathy and other brain insults. * infants who were lethargic and/or medically unstable and were generally unable to participate to protocol of assessment. * premature infants.